Damaskos Christos, Garmpis Nikolaos, Garmpi Anna, Nikolettos Konstantinos, Sarantis Panagiotis, Georgakopoulou Vasiliki E, Nonni Afroditi, Schizas Dimitrios, Antoniou Efstathios A, Karamouzis Michalis V, Nikolettos Nikos, Kontzoglou Konstantinos, Patsouras Alexandros, Voutyritsa Errika, Syllaios Athanasios, Koustas Evangelos, Trakas Nikolaos, Dimitroulis Dimitrios
Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece.
N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
J Pers Med. 2021 Jul 10;11(7):652. doi: 10.3390/jpm11070652.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10-20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.
三阴性乳腺癌（TNBC）是乳腺癌（BC）的一种侵袭性亚型，占病例的10%-20%。由于缺乏几种受体的表达，激素疗法在很大程度上对治疗无效。然而，TNBC通常对化疗反应良好，化疗是最常推荐的治疗方法。研究新的有益靶向疗法对于提高TNBC患者的治疗效果很重要。本综述将聚焦于TNBC的近期治疗创新，重点关注各种抑制剂，如磷酸肌醇3-激酶（PI3K）通路抑制剂、聚ADP核糖聚合酶（PARP）抑制剂、极光激酶抑制剂、组蛋白去乙酰化酶抑制剂（HDACIs）和免疫检查点抑制剂。
